Artee

Quick links to important sections

Artee

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artee

What is Artee?

Artee is a fixed-dose combination medication used primarily for the treatment of uncomplicated malaria. It consists of two active pharmaceutical ingredients: artemether and lumefantrine. These components work together to eliminate malaria parasites from the bloodstream.

Composition and Mechanism

  • Artemether: A derivative of artemisinin, this component acts rapidly to reduce the number of parasites during the initial stages of treatment.
  • Lumefantrine: This component has a longer half-life and works to clear any remaining parasites, helping to prevent the recurrence of the infection.

Therapeutic Use

This medication is specifically indicated for the treatment of acute, uncomplicated infections caused by Plasmodium falciparum, the most common species of malaria parasite. It is effective against strains that may be resistant to other older antimalarial treatments.

Artee is intended for use in both adults and children, with the primary goal of achieving a complete clinical cure by addressing the parasite at different stages of its life cycle within the human host.

What side effects are possible with Artee?

Possible Side Effects and Safety Information

This information is strictly based on the adverse reactions and safety constraints documented in official government regulatory materials for Artee (Artemotil) or related artemisinin derivatives. It does not contain clinical advice or instructions for use.


Officially Documented Adverse Reactions

The following non-serious adverse reactions are commonly reported, often categorized by the system they affect:

System/Organ Class (SOC) Adverse Reactions Listed on Labels
Nervous System Disorders Headache, Dizziness
Gastrointestinal Disorders Nausea, Vomiting, Anorexia
Musculoskeletal Disorders Arthralgia (Joint Pain), Myalgia (Muscle Pain)
General & Administration Site Pain or Swelling at the Injection Site, Fever
Blood Disorders Eosinophilia (increase in a type of white blood cell)

Safety Constraints and Serious Considerations

Regulatory documents highlight specific safety constraints and potential serious reactions, though frequencies may be rare or unknown:

  • Cardiac Risk: There is a potential for QT interval prolongation, a heart rhythm concern associated with artemisinin derivatives, leading to caution with certain co-administered medications.
  • Neurotoxicity: While neurotoxicity has been reported in high-dose animal studies, official labeling notes that there is no evidence of this effect in human beings at therapeutic doses.
  • Hypersensitivity: The medicine is contraindicated in patients with a known allergy to artemisinin derivatives or to the oily base (such as sesame oil) used in the formulation.

Population-Specific Safety Notes

  • Pregnancy: The medication is generally not recommended in the first trimester. Use in the second and third trimesters is restricted to cases of severe malaria where the potential benefit is judged to outweigh the potential risk to the fetus.
  • Lactation: It is not known whether the drug is excreted in human milk; caution is advised.
  • Organ Impairment: The use of Artemotil in patients with pre-existing severe renal or liver failure has not been sufficiently studied in clinical trials for severe parasitic infections.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The management of Artee (Artemotil) overdose is strictly based on the recognized toxicity profile of artemisinin derivatives, as documented in regulatory sources.


Documented Manifestations and Systems of Concern

Overdose Scope Official Regulatory Statement
Documented Presentations Manifestations that may be observed include nausea, vomiting, and dizziness or depressed gastrointestinal (GIT) activity (NAFDAC SmPC).
Physiological Systems Affected High exposure carries potential risks to the Central Nervous System (CNS) and Cardiovascular System. Cardiac conduction disturbances, such as QT interval prolongation, have been noted as a potential risk with high dosage.
Treatment Constraint No specific antidote is known for Artemotil overdose, limiting clinical intervention to supportive measures.

Immediate Actions and Regulatory Requirements

Any suspected overdose requires immediate medical attention. Since no antidote exists, the regulatory instruction mandates that treatment should be symptomatic and supportive to maintain vital functions.

When immediate medical help is required, the individual should contact Emergency Services or a Poison Control Center. Due to the systemic risks associated with high dosage, specialized clinical, neurological, and cardiovascular monitoring (such as ECG) may be required in a hospital setting for continued observation and management of emerging symptoms.

Therapeutic Uses of Artee

What Artee Addresses: Main Uses and Benefits

Artee is an antiparasitic medication used to address symptoms associated with malaria, an infection caused by a parasite. The primary therapeutic domains for its use include supporting the care of acute, uncomplicated presentations of falciparum malaria and certain presentations of chloroquine-resistant malaria.

Its use is particularly relevant in clinical scenarios where a patient cannot tolerate oral medication, requiring parenteral (non-oral) administration. The intended benefit is that the medicine may assist in the mitigation of associated symptoms of malaria, such as high fever, chills, and body aches, by influencing the parasite load.


Quick Fact: Relief for Malarial Fever

Regulatory References

  1. NIH MedlinePlus drug guidance

Eligibility and Restrictions for Use

The regulatory status of products marketed as Artee or similar names (e.g., Artri King) is defined by official governmental prohibition. Regulatory agencies, including the U.S. FDA and others, have issued public warnings that these products are unapproved new drugs and misbranded because they contain undeclared, potent prescription medications, such as the corticosteroid dexamethasone and the non-steroidal anti-inflammatory drug (NSAID) diclofenac.

Eligibility Status

Classification Status According to Regulatory Bodies
Use Allowed None. Use is formally discouraged for all populations.
Use Contraindicated Individuals with known NSAID hypersensitivity or severe systemic fungal infections (due to hidden ingredients).

Condition-Specific Restrictions

The presence of undeclared drugs imposes eligibility limitations found in their official labeling. Use is typically contraindicated in patients with a history of gastrointestinal bleeding/ulceration or those undergoing Coronary Artery Bypass Graft (CABG) surgery. Caution is required for patients with diabetes, hypertension, or renal/hepatic impairment.

Age and Physiological States

  • Pediatric Use: Not established/Not approved due to the unapproved nature of the product and the risks of hidden potent drugs in children.
  • Pregnancy/Lactation: Use is generally contraindicated or not recommended, particularly in the third trimester of pregnancy, due to risks associated with the undeclared NSAID and corticosteroid components.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Artee (Artemotil) Injection is primarily defined by a specific Pharmacodynamic Interaction and the absence of explicit documentation for certain other interaction types for this formulation.

Pharmacodynamic Interaction Profile

Artee must be administered with caution alongside other medicinal products known to prolong the QT interval. This restriction is based on the risk of an additive effect on cardiac repolarization, which is a key consideration noted by regulatory authorities for antimalarial agents.

  • Specific Interacting Agents: Official prescribing information cites antimalarial drugs such as Quinine and Halofantrine as specific examples of agents that require clinical consideration when used with Artee due to the potential for this additive effect.
  • Restriction Classification: Co-administration with other QT-prolonging drugs is generally restricted to avoid potential cardiac rhythm risks.

Other Interaction Domains

  • Pharmacokinetic Interactions: No specific patterns of enzyme-mediated metabolism (e.g., CYP450) or transporter-mediated interactions are documented in the official regulatory labels for Artee Injection. The clearance or plasma exposure of Artee is not officially stated to be significantly modified by co-administered medicinal products.
  • Administration Timing and Food: No mandatory time-based separation rules or restrictions regarding co-administration with food, alcohol, or herbal products are documented for the intramuscular injection formulation.

Mechanism of Action

Iron-Activated Chemical Warfare and Radical Generation

This mechanism initiates with the drug's essential interaction with high concentrations of ferrous iron ( Fe^2+) inside the parasite, an essential chemical catalyst. This interaction instantly cleaves the drug's endoperoxide bridge, resulting in the rapid generation of short-lived, highly reactive free radicals. This action dictates the chemical selectivity of the drug, as the parasite's necessity to process iron initiates the destruction of the parasite.


Non-Specific Protein Alkylation and Parasite Lysis

The reactive free radicals act as a non-specific chemical agent, rapidly forming covalent adducts (irreversible chemical bonds) with multiple essential parasitic proteins and structures, including key enzymes like PfATP6. This process of alkylation causes simultaneous and widespread cellular injury, leading to rapid cell failure and lysis (destruction) of the parasite. This multi-target attack arrests schizogony, resulting in the physiological consequence of a potent blood schizonticide effect.


Mechanistic Limitations on Stage Specificity

The mechanism is intrinsically limited by the requirement for a high iron concentration, meaning the drug’s mechanistic action is focused almost entirely on the asexual erythrocytic stages of the parasite that actively digest hemoglobin. This stage specificity inherently results in functionally constrained activity against the dormant hepatic stages (hypnozoites) and mature gametocytes, which do not concentrate the necessary iron.

Dosage and Administration Information

The usage of Artee, an injectable antimalarial derived from artemisinin, follows a specific protocol to standardize parenteral administration. The medicine is exclusively administered via intramuscular (IM) injection into a large muscle mass, such as the gluteal or quadriceps muscle; administration by the intravenous (IV) route is strictly forbidden. The solution is supplied in an oily base and requires no dilution prior to injection, though administration must be performed under aseptic conditions. Pediatric dosing uses the same weight-based regimen as adults.

Official Dosing and Schedule

The dosing schedule follows a weight-based protocol for injectable artemisinin derivatives. The regimen begins with an initial loading dose of 3.2 mg per kilogram (mg/kg) of body weight on Day 1. This is followed by a maintenance dose of 1.6 mg/kg body weight administered once daily on subsequent days.

Treatment Transition Protocol

The administration protocol defines Artee as a short-term initial therapy. Parenteral treatment is required for a minimum of 24 hours (two doses). The standard protocol requires that patients transition to a full course of oral therapy—typically an Artemisinin-based Combination Therapy (ACT)—as soon as they are able to swallow and retain oral medication. Continuous parenteral treatment should generally not exceed seven days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Artee (Artemotil)

The clinical evaluation of Artee (Artemotil) was studied for use in acute parasitic infections. The evidence base consists of randomized controlled trials (RCTs) and systematic reviews, and findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.


Evidence for Use in Severe Plasmodium falciparum Malaria

Research examined the use of injectable Artemotil in severe, life-threatening forms of the infection. Studies was studied for outcomes like overall mortality/survival rates and Parasite Clearance Time (PCT). The trials reported measurements of mortality that varied across study groups. Comparative evidence is lacking to draw clear, consistent patterns regarding survival compared to other treatments. The total number of trials and study populations were modest, and certainty remains low for definitive conclusions about mortality.

Evidence for Use in Acute Uncomplicated Plasmodium falciparum Malaria

Research has also explored the use of Artemotil in non-severe malaria, with studies examining outcomes related to systemic or functional imbalance. Endpoints research examined included time measured for fever clearance and the incidence of parasite recurrence (relapse) over defined intervals. Findings describe patterns observed in the studies consistent with action against the parasite’s blood stages, including specific measurements of parasite clearance.

Research Gaps and Uncertainty

The follow-up durations for most key trials are limited to the acute phase (28 to 42 days). Consequently, long-term effects are not fully established, particularly regarding durability or potential neurological sequelae that may only become apparent later. Evidence in special patient groups (such as pregnant women or those with specific comorbid conditions) remains insufficient. Evidence quality varies across studies, and comparative evidence is lacking against the newest combination therapies, meaning research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Artee (FAQ)

Q: Is Artee the same as that other drug I heard about?

A: Artee is the brand name for the active ingredient, Artemotil, which is also known as beta-Arteether. Official documents classify it in the same therapeutic family as other artemisinin-based antimalarial medicines. While all drugs in this class share a similar chemical foundation, Artee is a specific formulation (injection) used in particular clinical situations.

Q: Can Artee cause me to feel dizzy?

A: Official regulatory labels indicate that dizziness is one of the non-serious adverse reactions reported with Artee. These lists describe general patterns observed in studies. Concerns about any experienced effects should be discussed with a healthcare provider.

Q: Are there common side effects I should be aware of with Artee?

A: Regulatory documents list a range of non-serious adverse reactions that are commonly reported. These often include headache, nausea, vomiting, joint pain, and pain or swelling at the injection site. Regulatory documents list these as non-serious adverse reactions commonly reported in clinical settings.

Q: Does Artee interact with cold and flu medicine?

A: Official prescribing information does not list explicit interactions with most common over-the-counter cold and flu medicines. The primary interaction risk documented is with medicines known to prolong the heart's QT interval, which can occur with certain antimalarial drugs like Quinine.

Q: Can Artee affect my sleep pattern?

A: The listed adverse reactions for the nervous system mainly include headache and dizziness. Sleep pattern changes, such as insomnia, are not typically listed among the commonly reported side effects in the official regulatory profile for this medicine.

Q: Is Artee safe to take during pregnancy?

A: Official safety constraints state that Artee is generally not recommended for use during the first trimester of pregnancy. For the second and third trimesters, its use is restricted to cases of severe malaria where the potential health benefit is noted to outweigh the potential risk.

Q: What if I have kidney problems, can I still take Artee?

A: Regulatory information notes that Artee has not been sufficiently studied in clinical trials for patients who already have pre-existing severe renal (kidney) failure. Use in this group is approached with caution because specific clinical trials for patients with severe renal failure are noted as insufficient in regulatory documentation.

Q: Does Artee affect liver function?

A: Official documents advise caution, stating that the medicine has not been sufficiently studied in patients with pre-existing severe liver failure. Due to the limitation in available research on severe liver failure patients, official documents note that use in this group is not well-established.

Q: Can Artee be taken with common vitamins?

A: The official regulatory profile for Artee Injection is focused on drug-drug interactions. It does not document any mandatory time-based separation rules or restrictions regarding co-administration with food, alcohol, herbal products, or common vitamins.

Q: What are the most serious warnings associated with Artee?

A: Regulatory documents highlight a potential for QT interval prolongation, which is a heart rhythm concern, particularly when combined with other similar medications. The drug is also strictly contraindicated for anyone with a known hypersensitivity (allergic reaction) to the drug itself or to the oily base used in the injection.

Q: Can I drive while taking Artee?

A: Because adverse reactions like headache and dizziness are reported in official documents, these effects could potentially influence driving ability. Official guidance often recommends caution regarding the operation of machinery or driving.

Q: What are the main contraindications listed for Artee?

A: The primary contraindication (reason the drug must not be used) listed in the official label is a known hypersensitivity or allergy to artemisinin derivatives or to the oily base used in the formulation.

Q: Does Artee cause weight gain or loss?

A: Weight changes are not explicitly listed as a side effect on the official regulatory label. However, the list of adverse reactions includes anorexia (loss of appetite), which is a common effect observed in studies.

Q: How quickly does Artee start to work?

A: Official information indicates that the medicine is absorbed rapidly following intramuscular injection. Studies indicate the active substance typically reaches maximum concentration in the blood within 4 to 9 hours, reflecting its rapid systemic uptake.

Q: How long do you usually take Artee for?

A: The parenteral treatment protocol is defined as a short-term initial therapy, generally lasting a few days, and should not exceed the maximum duration specified in official documents before a patient transitions to a full course of oral therapy.

Q: Does Artee have a risk of addiction or dependence?

A: Artee is classified as an antimalarial drug. Official regulatory documents do not list dependence or addiction as a known risk, warning, or side effect associated with the use of this therapeutic class.

Q: How is Artee different from a supplement?

A: Unlike supplements, which are largely unregulated, Artee is a pharmaceutical drug that has undergone official regulatory review, testing, and approval by governmental health agencies. Its manufacture, quality, and use conditions are strictly controlled.

Q: What is the common age range for people using Artee?

A: The official documentation provides specific weight-based dosing schedules that apply to both adults and children. This indicates that the medicine is intended for use in pediatric and adult populations, subject to the medical diagnosis.

Q: Is Artee available over-the-counter?

A: Artee is supplied as a sterile solution for intramuscular injection and is administered under a specific medical protocol, primarily in a supervised setting. Because of this specialized use, it is available by prescription only and is not an over-the-counter medicine.

Q: Is it normal to feel a bit tired when starting Artee?

A: While tiredness (fatigue) is not specifically listed on the common side effects list in official documents, other effects that may cause a feeling of malaise, such as dizziness or headache, are reported. Official documentation is limited to adverse reactions reported during clinical development and does not list fatigue or tiredness among the commonly experienced effects.

Q: Does Artee stay in your system for a long time?

A: The active substance of Artee is converted in the body to an active metabolite. This compound has an estimated elimination half-life of approximately 20 hours, indicating its clearance rate from the body.

Q: Are there any specific lifestyle changes recommended while taking Artee?

A: The official regulatory information is primarily concerned with drug-drug interactions. It does not document mandatory lifestyle changes or restrictions regarding co-administration with food, alcohol, or herbal products for the intramuscular injection formulation.

Q: What is the shelf life of Artee?

A: Official storage conditions specify that the unopened medicine has a shelf life of 36 months (three years). This duration requires that the medicine be stored correctly, specifically below 30 C and protected from light and moisture.

Q: Is it possible for Artee to cause a skin rash?

A: While skin rash is not listed among the commonly reported side effects, regulatory documents highlight that hypersensitivity (an allergic reaction) to the drug or its components is a serious safety consideration. A rash could be a sign of such a reaction.

Q: Can Artee be crushed or split?

A: No. Artee is strictly supplied as a non-aqueous solution for intramuscular injection and must be used as formulated. It is not intended to be diluted, crushed, or split.

Q: What is the reason Artee is not for everyone?

A: Artee is not used in all cases due to official contraindications and specific safety precautions. The main reason for exclusion is a known allergy to the medicine. Caution is also advised in patient groups with severe organ impairment or those in the early stages of pregnancy.

Q: Is the benefit of Artee proven by science?

A: Research has studied the use of Artee in severe parasitic infections, examining outcomes like survival rates and parasite clearance time. The drug is officially classified as a blood schizonticide, meaning its action to clear parasites in the blood is recognized in pharmacological documents.

Q: How long until the full effect of Artee is expected?

A: Official information defines the drug’s intended therapeutic effect as the rapid clearance of malaria parasites from the bloodstream. Research studies examine outcomes like the measured Parasite Clearance Time, which is the key measure of this action.

Q: Does Artee interact with birth control pills?

A: The official regulatory label for Artee Injection does not document a specific interaction with hormonal contraceptives. However, regulatory documents for similar drugs in the same class sometimes include warnings that advise the use of an additional, non-hormonal method of birth control.

Q: What are the most common reasons Artee might be discontinued?

A: The most common and expected reason for discontinuation is the planned transition to oral therapy. The official protocol states that the injection treatment must be stopped after a maximum specified duration, or as soon as the patient is able to swallow oral medication.

Q: Where can I find the official patient leaflet for Artee?

A: The official patient information leaflet (PIL) is generally required to be included in the medicine's packaging. You can also typically find the official, medically reviewed documentation on the websites of the national regulatory agency that approved Artee for use in your specific country.

How should Artee be stored and disposed of?

How to Store and Dispose of Artee

The storage and disposal of Artee (Artemotil injection) must strictly follow the requirements stated in the official regulatory labeling to ensure its stability and safe handling.

Official Storage Conditions

Requirement Specification
Temperature Store below 30 C. Do not freeze the solution.
Protection Protect from light; store in a dry place.
Container Store in the original package to maintain light protection.
Safety Keep out of the sight and reach of children.
Stability The unopened shelf life is 36 months when stored as directed.

Disposal Requirements

Artee is for single use only. Any unused product or waste material remaining in the ampoule must be discarded immediately after use. Disposal of the expired or unused medicine must be performed in accordance with local requirements established for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artee found in:

A-Z Index: